Kerri Fitzgerald

DocwireNews

A study published in the <a href="http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.34_suppl.140">Journal of Clinical Oncology</a> found that Medicare beneficiaries with lung cancer who switch from reference filgrastim to the biosimilar filgrastim-sndz may have reduced out-of-pocket costs.The granulocyte-colony stimulating factor filgrastim-sndz was the first biosimilar to receive U.S. Food and Drug Administration approval. However, there are limited data on the impact of biosimilars use and out-of-pocket expenditures.Researchers conducted a simulation model to estimate potential out-of-pocket cost savings with filgrastim-sndz compared with reference filgrastim in a cohort of Medicare beneficiaries with lung cancer who were identified via HCPCS codes. They used data from the 2016 Medicare Limited Data Set to create the Excel model to calculate the average Medicare payment to provider and beneficiary out-of-pocket responsibility. The average out-of-pocket reduction per claim for filgrastim-sndz relative to the reference filgrastim was multiplied to a hypothetical febrile neutropenia prevalent population of 100,000 beneficiaries, with an assumed average of 10 claims per beneficiary, to estimate the potential out-of-pocket savings.The researchers used data from 525 patients receiving filgrastim-sndz and 621 patients receiving the reference agent. The average amount allowed by Medicare per claim for a beneficiary receiving filgrastim-sndz was $381.70 compared with $419.10 for a beneficiary receiving the reference agent. The corresponding average Medicare payments to the provider were $299.30 and $327.40, respectively.On an average, out-of-pocket responsibility for a beneficiary receiving filgrastim-sndz was lower than those receiving the reference agent ($76.40 vs $85.00), resulting in a cost saving per claim of approximately $8.60 for the biosimilar cohort.Researchers extrapolated this finding to 100,000 beneficiaries and indicated that the overall cost saving was approximately $8.6 million.The researchers noted that further real-world analyses are required to evaluate the true cost savings potential of biosimilar agents.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Reduced Out-of-Pocket Costs With Biosimilar Filgrastim for Medicare Beneficiaries

Oncology

A study published in the Journal of Clinical Oncology found that Medicare beneficiaries with lung cancer who switch from reference filgrastim to the biosimilar filgrastim-sndz ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe